[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,710,208
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.76
  • Price/Sales 4.49
  • Price/Cash Flow 10.05
  • Price/Book 6.61

Options Overview Details

View History
  • Implied Volatility 35.58% (-6.22%)
  • Historical Volatility 39.53%
  • IV Percentile 1%
  • IV Rank 0.33%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 2) 0.94 (2.12%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 92,207
  • Volume Avg (30-Day) 57,365
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 1,477,644
  • Open Int (30-Day) 1,344,527
  • Expected Range 43.59 to 45.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.78
  • Number of Estimates 4
  • High Estimate $0.85
  • Low Estimate $0.74
  • Prior Year $1.02
  • Growth Rate Est. (year over year) -23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.68 +1.95%
on 08/04/26
52.12 -14.55%
on 07/29/26
-5.90 (-11.70%)
since 07/02/26
3-Month
41.00 +8.61%
on 06/08/26
52.12 -14.55%
on 07/29/26
-0.34 (-0.76%)
since 05/05/26
52-Week
35.12 +26.79%
on 03/30/26
64.16 -30.60%
on 01/23/26
-2.69 (-5.70%)
since 08/05/25

Most Recent Stories

More News
Novo Nordisk Reports Tomorrow With Injectable GLP-1 Durability Under Scrutiny

Barchart Research What to Expect from NVO Earnings NVO Generated August 4, 2026 Current Price $44.28 EPS Estimate $$0.81 Consensus Rating Hold Average Move 4.38% Novo Nordisk Reports Tomorrow With Injectable...

NVO : 44.53 (+0.56%)
Bearish Pressure Is Building Around These 3 Stocks

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

KLAC : 192.80 (-1.36%)
TSLA : 321.55 (-1.77%)
HIMS : 31.65 (-1.59%)
NVO : 44.53 (+0.56%)
QXO : 15.90 (+3.65%)
SKHY : 151.03 (-2.17%)
Jobs Numbers Set for Release Next Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...

SONY : 22.44 (+0.40%)
SNDK : 1,350.50 (-5.40%)
COP : 115.04 (-2.46%)
NVO : 44.53 (+0.56%)
CAT : 871.08 (-0.62%)
MRK : 128.33 (+0.26%)
VRTX : 484.83 (+1.28%)
AMD : 482.05 (-7.04%)
LLY : 1,169.86 (+4.86%)
PH : 996.90 (+0.43%)
PLTR : 158.43 (-2.60%)
MAR : 361.31 (+4.67%)
NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

NVO : 44.53 (+0.56%)
LLY : 1,169.86 (+4.86%)
HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

META : 588.77 (+0.14%)
HIMS : 31.65 (-1.59%)
NVO : 44.53 (+0.56%)
SNAP : 5.33 (-7.94%)
Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly's advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo's latest...

NVO : 44.53 (+0.56%)
LLY : 1,169.86 (+4.86%)
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

AVAI : 0.1201 (-7.62%)
TNDM : 19.59 (-3.02%)
NVO : 44.53 (+0.56%)
DXCM : 82.66 (-4.92%)
SNY : 42.78 (+0.23%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 160.33 (+0.01%)
CLDX : 41.06 (+5.15%)
PGEN : 6.89 (+5.51%)
NVO : 44.53 (+0.56%)
AKAM : 122.27 (-0.88%)
SNEX : 76.02 (+1.05%)
ORCL : 144.39 (-0.93%)
ABBV : 246.20 (+0.98%)
GDXJ : 109.48 (+7.42%)
RSP : 219.73 (-0.23%)
VKTX : 33.51 (+1.73%)
LLY : 1,169.86 (+4.86%)
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

HIMS : 31.65 (-1.59%)
NVO : 44.53 (+0.56%)
LLY : 1,169.86 (+4.86%)
MSFT Stock Alert: Microsoft Invests $2.5 Billion in AI Implementation Unit

Microsoft shares soar as the behemoth announces a $2.5 billion investment in a new initiative, Microsoft Frontier Co. But does that warrant buying MSFT stock today?

MSFT : 487.46 (-1.09%)
NVO : 44.53 (+0.56%)
UL : 64.43 (+0.55%)
AMZN : 272.65 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 46.71
2nd Resistance Point 46.22
1st Resistance Point 45.37
Last Price 44.53
1st Support Level 44.03
2nd Support Level 43.54
3rd Support Level 42.69

See More

52-Week High 64.16
Fibonacci 61.8% 53.07
Fibonacci 50% 49.64
Fibonacci 38.2% 46.21
Last Price 44.53
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.